Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

BETA DIAGNOSTIC LABS LLC

NPI: 1457003329 · MT PLEASANT, WI 53406 · Clinical Medical Laboratory · NPI assigned 01/21/2022

$8.44M
Total Medicaid Paid
254,489
Total Claims
58,215
Beneficiaries
27
Codes Billed
2022-06
First Month
2024-06
Last Month

Provider Details

Authorized OfficialTOUSIS, TOM (OWNER)
NPI Enumeration Date01/21/2022

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2022 45,529 $1.43M
2023 205,234 $6.95M
2024 3,726 $67K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 51,495 10,280 $4.80M
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 22,839 4,586 $714K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 18,024 4,420 $609K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 16,796 4,235 $578K
87634 18,043 4,415 $435K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 50,844 9,145 $338K
87581 18,284 4,623 $236K
87486 17,905 4,591 $230K
87541 17,956 4,593 $228K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 17,141 4,271 $180K
87640 1,834 1,043 $26K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 328 128 $15K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 300 230 $12K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 362 139 $6K
87536 189 116 $3K
87529 92 72 $3K
87625 207 133 $3K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 205 133 $3K
87623 207 133 $3K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 205 133 $3K
87496 203 131 $3K
87517 175 107 $2K
87522 Neg quan hep c or qual rna 190 117 $2K
87497 194 122 $2K
87521 Neg quan hep c or qual rna 200 127 $2K
87516 185 117 $2K
87535 86 75 $1K